Total Payments
$9,669
2024 Payments
$439.78
Companies
41
Transactions
730
Medicare Patients
4,312
Medicare Billing
$512,939
Payment Breakdown by Category
Food & Beverage$9,663 (99.9%)
Education$6.02 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,663 | 729 | 99.9% |
| Education | $6.02 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $2,832 | 182 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $874.14 | 56 | $0 (2020) |
| PFIZER INC. | $846.86 | 83 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $459.59 | 26 | $0 (2020) |
| Allergan, Inc. | $454.16 | 62 | $0 (2020) |
| Merck Sharp & Dohme LLC | $406.66 | 39 | $0 (2023) |
| Novo Nordisk Inc | $383.49 | 27 | $0 (2023) |
| Amgen Inc. | $374.11 | 21 | $0 (2021) |
| ABBVIE INC. | $373.21 | 33 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $286.21 | 25 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $439.78 | 24 | GlaxoSmithKline, LLC. ($283.34) |
| 2023 | $650.23 | 39 | GlaxoSmithKline, LLC. ($383.33) |
| 2022 | $878.07 | 53 | GlaxoSmithKline, LLC. ($500.94) |
| 2021 | $1,067 | 77 | GlaxoSmithKline, LLC. ($490.09) |
| 2020 | $1,103 | 75 | GlaxoSmithKline, LLC. ($369.50) |
| 2019 | $1,214 | 91 | GlaxoSmithKline, LLC. ($357.38) |
| 2018 | $1,983 | 160 | GlaxoSmithKline, LLC. ($329.67) |
| 2017 | $2,334 | 211 | PFIZER INC. ($238.74) |
All Payment Transactions
730 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | Kowa Pharmaceuticals America, Inc. | ZORYVE (Drug) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: DERMATOLOGY | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: VACCINES | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: RESPIRATORY | ||||||
| 11/08/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: VACCINES | ||||||
| 10/24/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: RESPIRATORY | ||||||
| 10/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: RESPIRATORY | ||||||
| 08/06/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: PAIN | ||||||
| 07/23/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: RESPIRATORY | ||||||
| 07/16/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $23.02 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/12/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: RESPIRATORY | ||||||
| 06/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: RESPIRATORY | ||||||
| 05/20/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: RESPIRATORY | ||||||
| 05/01/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: RESPIRATORY | ||||||
| 04/15/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: PAIN | ||||||
| 04/01/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: RESPIRATORY | ||||||
| 02/26/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: RESPIRATORY | ||||||
| 02/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: RESPIRATORY | ||||||
| 02/16/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: PAIN | ||||||
| 01/30/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: RESPIRATORY | ||||||
| 01/24/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: RESPIRATORY | ||||||
| 01/18/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: RESPIRATORY | ||||||
| 12/12/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 880 | 1,774 | $220,309 | $94,837 |
| 2022 | 21 | 1,075 | 2,132 | $254,710 | $123,416 |
| 2021 | 26 | 1,194 | 2,346 | $281,396 | $138,874 |
| 2020 | 23 | 1,163 | 2,499 | $325,423 | $155,811 |
Total Patients
4,312
Total Services
8,751
Medicare Billing
$512,939
Procedure Codes
89
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 101 | 358 | $49,740 | $21,615 | 43.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 139 | 273 | $36,855 | $15,266 | 41.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 109 | 109 | $16,350 | $13,156 | 80.5% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Office | 2023 | 57 | 427 | $46,310 | $10,414 | 22.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 64 | 73 | $13,190 | $7,206 | 54.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 73 | $13,145 | $6,652 | 50.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 55 | 78 | $11,284 | $4,749 | 42.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 55 | $9,540 | $3,911 | 41.0% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 16 | 19 | $6,570 | $3,902 | 59.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 16 | $4,300 | $2,124 | 49.4% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 113 | 113 | $2,825 | $1,902 | 67.3% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 19 | 19 | $2,490 | $1,440 | 57.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 25 | 25 | $750.00 | $724.75 | 96.6% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 14 | 14 | $1,600 | $591.28 | 37.0% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 11 | 13 | $1,300 | $424.16 | 32.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 11 | 31 | $1,860 | $351.12 | 18.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 20 | 26 | $910.00 | $239.42 | 26.3% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2023 | 12 | 25 | $750.00 | $110.12 | 14.7% |
| 81003 | Automated urinalysis test | Office | 2023 | 21 | 27 | $540.00 | $59.40 | 11.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 109 | 468 | $56,160 | $26,165 | 46.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 133 | 133 | $19,950 | $16,822 | 84.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 125 | 269 | $36,330 | $16,365 | 45.0% |
| 99307 | Follow-up nursing facility visit per day, typically 10 minutes | Office | 2022 | 66 | 450 | $36,000 | $11,845 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 92 | 111 | $20,535 | $8,857 | 43.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 38 | 104 | $17,680 | $8,387 | 47.4% |
About Dr. Steve Gaudin, M.D
Dr. Steve Gaudin, M.D is a Family Medicine healthcare provider based in Ponchatoula, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1649269390.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steve Gaudin, M.D has received a total of $9,669 in payments from pharmaceutical and medical device companies, with $439.78 received in 2024. These payments were reported across 730 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($9,663).
As a Medicare-enrolled provider, Gaudin has provided services to 4,312 Medicare beneficiaries, totaling 8,751 services with total Medicare billing of $512,939. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Ponchatoula, LA
- Active Since 10/17/2005
- Last Updated 11/07/2008
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1649269390
Products in Payments
- TRELEGY ELLIPTA (Drug) $1,904
- APTIOM (Drug) $428.11
- ANORO (Drug) $400.23
- ELIQUIS (Drug) $392.87
- VRAYLAR (Drug) $314.24
- CHANTIX (Drug) $256.00
- JANUVIA (Drug) $238.71
- XIFAXAN (Drug) $231.58
- Victoza (Drug) $224.39
- LYRICA (Drug) $211.60
- Vascepa (Drug) $209.05
- XARELTO (Drug) $207.53
- ANORO ELLIPTA (Drug) $202.83
- UBRELVY (Drug) $192.87
- Aimovig (Biological) $158.57
- FARXIGA (Drug) $156.28
- SOLIQUA (Drug) $149.28
- LONHALA MAGNAIR (Drug) $146.37
- TRADJENTA (Drug) $145.47
- SYMBICORT (Drug) $138.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.